Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allogene Therapeutics (ALLO – Research Report), Zur Rose Group AG (CH:DOCM – Research Report) and Fresenius SE & Co. KGaA (GB:0OO9 – Research Report).
Allogene Therapeutics (ALLO)
In a report issued on June 4, Brian Cheng from J.P. Morgan reiterated a Buy rating on Allogene Therapeutics, with a price target of $11.00. The company’s shares closed last Wednesday at $4.69, close to its 52-week low of $4.30.
According to TipRanks.com, Cheng is a 3-star analyst with an average return of
Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.28, which is a 179.6% upside from current levels. In a report issued on May 26, EF Hutton also reiterated a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
Fresenius SE & Co. KGaA (GB:0OO9)
Jefferies analyst James Vane maintained a Buy rating on Fresenius SE & Co. KGaA yesterday and set a price target of EUR38.00. The company’s shares closed yesterday at EUR28.48, close to its 52-week low of EUR24.01.
Vane has an average return of
According to TipRanks.com, Vane is ranked #7745 out of 24810 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fresenius SE & Co. KGaA with an EUR36.28 average price target, a 27.9% upside from current levels. In a report issued on July 20, Kepler Capital also maintained a Buy rating on the stock with a EUR35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALLO:
- Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
- ‘Too Cheap to Ignore’: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
- Allogene Therapeutics price target lowered to $18 from $20 at Truist
